MF-300

DB32060InvestigationalSmall molecule

MF-300 is an orally bioavailable 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor used to treat sarcopenia by reducing the enzymatic degradation of prostaglandin E2. As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.

Mechanism: Pharmacologically active on 15-hydroxyprostaglandin dehydrogenase [NAD(+)]
Curator reviewed
Code names: MF-300

Resolves to

Targets

P15428HPGD

What you can answer from here — as of June 04, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with MF-300, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account